DoW Toxic Exposures Clinical Trial Award
About
Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e. g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations. Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts. https://cdmrp. health. mil/pubs/press/2026/terppreann.
The DoW Toxic Exposures Clinical Trial Award, administered through the Department of Defense's Toxic Exposures Research Program (TERP), supports clinical researchers and institutions conducting trials to address military-related toxic exposures. This grant mechanism funds projects ranging from small proof-of-concept and pilot studies to large-scale pragmatic clinical trials designed to improve prevention, treatment, or symptom management for service members and veterans. Researchers should apply if they are developing interventions with significant potential impact on health outcomes related to toxic exposure in military populations. The FY26 funding cycle uniquely emphasizes interdisciplinary collaborations through its Partnering Principal Investigator Option, allowing two PIs from different fields—such as clinicians and research scientists—to jointly lead research that advances beyond what independent efforts could achieve. This collaborative structure accelerates the translation of promising interventions into clinical applications. Eligible institutions include academic medical centers, research organizations, military medical facilities, and other entities capable of conducting rigorous clinical trials. The grant supports all phases of clinical development, making it ideal for researchers ready to move promising discoveries from laboratory findings into human testing and efficacy evaluation in relevant patient populations affected by military-related toxic exposures.
Funding Facts
● Applications openDeadline
November 19, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by cycle and project scope
Deadline
2026-11-19
Grant Type
federal
Application Cycle
Annual - FY26 deadline November 19, 2026
Best For
Research institutions, academic medical centers, and clinical researchers conducting trials on military-related toxic exposures; interdisciplinary research teams with partnering PIs
Frequently Asked Questions
Who is eligible for DoW Toxic Exposures Clinical Trial Award?
Specific eligibility criteria are not detailed in the available information. Typically, such DoD grants support academic institutions, research organizations, medical centers, and affiliated researchers. For current and complete eligibility requirements, including institutional qualifications, researcher credentials, and any restrictions, visit the official CDMRP announcement at https://cdmrp.health.mil/pubs/press/2026/terppreann
How much funding does DoW Toxic Exposures Clinical Trial Award provide?
The specific funding amount for FY26 is not listed in the pre-announcement. Award amounts typically vary based on project scope, study phase, and trial complexity. For detailed information about funding ranges and budget limits, consult the full funding announcement on the CDMRP website.
How do I apply for DoW Toxic Exposures Clinical Trial Award?
Applications are submitted through the DoD's standard grant portal. The deadline for FY26 is November 19, 2026. For specific application instructions, required documentation, submission procedures, and the full request for proposals, visit https://cdmrp.health.mil/pubs/press/2026/terppreann. Applications should clearly describe the clinical trial design, toxic exposure focus, expected outcomes, and how partnering PIs (if applicable) will collaborate.
What can DoW Toxic Exposures Clinical Trial Award funding be used for?
Funding supports the advancement, execution, and analysis of clinical trials addressing military-related toxic exposures. Acceptable projects include proof-of-concept trials, pilot studies, first-in-human trials, and large-scale efficacy trials designed to prevent, treat, or manage diseases and symptoms resulting from toxic exposure. The award also emphasizes interdisciplinary research collaborations that accelerate the movement of interventions into clinical applications. For a complete list of allowable expenses and use restrictions, refer to the official funding announcement.
Last updated: July 5, 2026